Joe Bress is a Managing Director on the U.S. Buyout team focused on private equity investments in the healthcare sector.
Since joining Carlyle in 2007, Mr. Bress has been involved in investing and managing over $5 billion of equity investments into healthcare companies globally. He is currently a member of the boards of Curia, CorroHealth, Launch Therapeutics, Millicent Pharma, Orsini Specialty Pharmacy, Saama Technologies, TriNetX, and WellDyneRx. He is also involved in Carlyle’s broader life sciences efforts, including the recent acquisition of Abingworth, as well as Carlyle’s investments in Included Health and Rede D’Or Sao Luiz. He was previously a member of the boards of Pharmaceutical Product Development (PPD), Visionary RCM and X-Chem. Prior to Carlyle, Mr. Bress worked in the Mergers & Acquisitions group at UBS.
He received an MBA from Stanford University’s Graduate School of Business and an AB from Harvard College, where he graduated magna cum laude.